{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:08:21Z","timestamp":1777100901061,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our aims were to determine if the Psoriasis Area Severity Index (PASI) score and serum urate (SU) levels were associated at baseline and whether the change in PASI score during 12\u2009weeks of treatment resulted in a significant change in SU, adjusted for relevant confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from patients with psoriasis\/PsA (n\u2009=\u20091042\/204) in three phase 3 randomized control trials treated with secukinumab (dose 300\u2009mg, n\u2009=\u2009628) or placebo (n\u2009=\u2009414) were pooled. At baseline, values for SU, PASI and the following covariates were assessed: age, sex, BMI, estimated glomerular filtration rate, and medication with diuretics. To assess the changes in PASI (\u0394PASI) and SU (\u0394urate), the differences (week\u200912 minus baseline) in patients receiving the active drug were used. Multivariable linear regression, adjusting for covariates, was used to assess the association between PASI and SU at baseline with all patients pooled and to assess the association between \u0394urate and \u0394PASI over 12\u2009weeks of treatment with secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The degree of skin involvement of psoriasis showed a statistically significant, albeit modest, association with SU (R2\u2009=\u20090.014, P\u2009&amp;lt;\u20090.0001 univariately), whereas known risk factors for hyperuricaemia had a much larger impact cross-sectionally at baseline (R2 = 0.33, P\u2009&amp;lt;\u20090.0001). Furthermore, a substantial improvement in PASI score resulted in only a modest decrease of SU over 12\u2009weeks of treatment with secukinumab (R2\u2009=\u20090.014, P\u2009&amp;lt;\u20090.0001 univariately).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is a statistically significant, albeit modest, association with both extent and change in PASI score and SU in patients with psoriasis, compatible with a potential pathophysiological relationship between urate and psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial Registration<\/jats:title>\n                  <jats:p>ERASURE: clinicaltrials.gov, https:\/\/clinicaltrials.gov, NCT01365455; FIXTURE: clinicaltrials.gov, https:\/\/clinicaltrials.gov, NCT01358578; SCULPTURE: clinicaltrials.gov, https:\/\/clinicaltrials.gov, NCT01406938<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab009","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T11:33:16Z","timestamp":1613647996000},"source":"Crossref","is-referenced-by-count":6,"title":["Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis\u2014a <i>post-hoc<\/i> analysis of pooled data from three phase 3 trials with secukinumab"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-0968","authenticated-orcid":false,"given":"Mats","family":"Dehlin","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas E R","family":"Fasth","sequence":"additional","affiliation":[{"name":"Medical Affairs, Novartis Sverige AB, Kista, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Reinhardt","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-148X","authenticated-orcid":false,"given":"Lennart T H","family":"Jacobsson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"2021031611302955000_rkab009-B1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review","volume":"8","author":"El Din","year":"2017","journal-title":"J Adv Res"},{"key":"2021031611302955000_rkab009-B2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021031611302955000_rkab009-B3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"2021031611302955000_rkab009-B4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI104643","article-title":"Interrelation of uric acid and ethanol metabolism in man","volume":"41","author":"Lieber","year":"1962","journal-title":"J Clin Invest"},{"key":"2021031611302955000_rkab009-B5","doi-asserted-by":"crossref","first-page":"k3951","DOI":"10.1136\/bmj.k3951","article-title":"Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts","volume":"363","author":"Major","year":"2018","journal-title":"BMJ"},{"key":"2021031611302955000_rkab009-B6","author":"Skinner","year":"2001"},{"key":"2021031611302955000_rkab009-B7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.ackd.2012.07.010","article-title":"Changes in serum urate and urate excretion with age","volume":"19","author":"Stiburkova","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"2021031611302955000_rkab009-B8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2013-203545","article-title":"Effect of bariatric surgery on the inflammatory response to monosodium urate crystals: a prospective study","volume":"72","author":"Dalbeth","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021031611302955000_rkab009-B9","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2021031611302955000_rkab009-B10","doi-asserted-by":"crossref","first-page":"e3676","DOI":"10.1097\/MD.0000000000003676","article-title":"Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis","volume":"95","author":"Li","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2021031611302955000_rkab009-B11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension"},{"key":"2021031611302955000_rkab009-B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","article-title":"Uric acid in metabolic syndrome: from an innocent bystander to a central player","volume":"29","author":"Kanbay","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2021031611302955000_rkab009-B13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021031611302955000_rkab009-B14","first-page":"1495","article-title":"Psoriasis, psoriatic arthritis and risk of gout in US men and women","author":"Merola","year":"2015"},{"key":"2021031611302955000_rkab009-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","article-title":"Uric acid as a danger signal in gout and its comorbidities","volume":"9","author":"Rock","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2021031611302955000_rkab009-B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12016-016-8535-x","article-title":"The inflammatory response in psoriasis: a comprehensive review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021031611302955000_rkab009-B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2021031611302955000_rkab009-B18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Eng J Med"},{"key":"2021031611302955000_rkab009-B19","first-page":"259","article-title":"Evaluating psoriasis: a review of the assessments most commonly used in clinical trials","author":"Patel","year":"2011"},{"key":"2021031611302955000_rkab009-B20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"2021031611302955000_rkab009-B21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/1203475415586332","article-title":"The relationship of obesity with the severity of psoriasis: a systematic review","volume":"19","author":"Fleming","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"2021031611302955000_rkab009-B22","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11255-018-1868-z","article-title":"Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis","volume":"50","author":"Ungprasert","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"2021031611302955000_rkab009-B23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021031611302955000_rkab009-B24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000372-198100340-00014","article-title":"Uric acid in the etiology of psoriasis","volume":"3","author":"Goldman","year":"1981","journal-title":"Am J Dermatopathol"},{"key":"2021031611302955000_rkab009-B25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10067-020-04981-0","article-title":"At the crossroads of gout and psoriatic arthritis: \u201cpsout.\u201d","volume":"39","author":"Felten","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2021031611302955000_rkab009-B26","doi-asserted-by":"crossref","first-page":"adv00030","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2021031611302955000_rkab009-B27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2021031611302955000_rkab009-B28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","article-title":"Global epidemiology of gout: prevalence, incidence and risk factors","volume":"11","author":"Kuo","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2021031611302955000_rkab009-B29","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab009\/36309890\/rkab009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/1\/rkab009\/36614910\/rkab009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumap\/article-pdf\/5\/1\/rkab009\/36614910\/rkab009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T12:25:22Z","timestamp":1615897522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab009\/6143046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab009","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021]]},"published":{"date-parts":[[2021]]},"article-number":"rkab009"}}